Disease and treatment outcome in chronic active hepatitis C with occult HBV infection.
To evaluate the clinical course and effect of antiviral treatment in chronic active hepatitis C with coexisting occult hepatitis B infection. Basic liver enzymes, histological activity of hepatitis (Ishak score), biochemical and virological response rate at the end of treatment and 6 months later of 30 patients (15 of them positive for hepatitis B core antibody in serum) with chronic active hepatitis C are compared. All patients were treated with Interferon alpha-2b 3ME three times weekly and oral Ribavirin 1000/1200 mg daily for six months. The pure hepatitis C group demonstrates markedly higher biochemical and histological (necroinflammatory) activity. After treatment the pure hepatitis C group shows normalization of serum ALT in 73% (vs. 66% in hepatitis B core antibody-positive patients); loss of detectable HCV-RNA in serum in 47% (vs. 35%) and sustained biochemical response 6 months later in 28% vs. 40% respectively. Patients with circulating hepatitis B core antibodies might develop some degree of immune tolerance against hepatitis C virus, with less advanced hepatolysis and necroinflammation even in the presence of HCV viremia and worse virological therapeutic response, associated with frequent sustained ALT normalization.